共 50 条
- [21] Assessment of EU4 laboratory readiness for FGFR2 fusion testing of cholangiocarcinoma by NGSANNALS OF ONCOLOGY, 2021, 32 : S379 - S379Sciortino, M.Atkey, N.Bisaro, B.Courtois, G.Holtkamp, N.Iparraguirre, J.Holt, B.Ricelli, P. V.Munksted, S.Clark, J.
- [22] Efficacy of derazantinib (DZB) in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) expressing FGFR2-fusion or FGFR2 mutations/amplificationsANNALS OF ONCOLOGY, 2019, 30Busset, M. Droz DitBraun, S.El-Rayes, B.Harris, W. P.Damjanov, N.Masi, G.Rimassa, L.Bhoori, S.Niger, M.Personeni, N.Braiteh, F.Lonardi, S.Engelhardt, M.Saulay, M.Schwartz, B.Shaib, W. L.Mazzaferro, V.Papadopoulos, K. P.
- [23] Postpartum related intrahepatic cholangiocarcinoma with FGFR2 fusion and severe hyperbilirubinemia with response to FGFR inhibitor pemigatinib: case report and reviewJOURNAL OF GASTROINTESTINAL ONCOLOGY, 2023, 14 (06) : 2627 - 2636Washburn, LeslieMahipal, AmitJatoi, AminahKottschade, LisaTran, Nguyen
- [24] Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapiesNPJ PRECISION ONCOLOGY, 2022, 6 (01)Lidsky, Michael E.Wang, ZechenLu, MinLiu, AnnieHsu, S. DavidMcCall, Shannon J.Sheng, ZhechengGranek, Joshua A.Owzar, KourosAnderson, Karen S.Wood, Kris C.
- [25] Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapiesnpj Precision Oncology, 6Michael E. LidskyZechen WangMin LuAnnie LiuS. David HsuShannon J. McCallZhecheng ShengJoshua A. GranekKouros OwzarKaren S. AndersonKris C. Wood
- [26] Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling testCLINICAL CASE REPORTS, 2023, 11 (07):Ishido, ShunTamaki, NobuharuInada, KentoItakura, JunTakahashi, YukaUchihara, NaokiSuzuki, KeitoTanaka, YukiMiyamoto, HarukaYamada, MichikoMatsumoto, HiroakiNobusawa, TsubasaKeitoku, TaiseiTakaura, KentaTanaka, ShoheiMaeyashiki, ChiakiYasui, YutakaTsuchiya, KaoruNakanishi, HiroyukiKurosaki, MasayukiIzumi, Namiki
- [27] HSP90 Inhibition Drives Degradation of FGFR2 Fusion Proteins: Implications for Treatment of CholangiocarcinomaHEPATOLOGY, 2019, 69 (01) : 131 - 142Lamberti, DanteCristinziano, GiuliaPorru, ManuelaLeonetti, CarloEgan, Jan B.Shi, Chang-XinBuglioni, SimonettaAmoreo, Carla A.Castellani, LorianaBorad, Mitesh J.Alema, StefanoAnastasi, SergioSegatto, Oreste
- [28] Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinomaBritish Journal of Cancer, 2019, 120 : 165 - 171Vincenzo MazzaferroBassel F. El-RayesMichele Droz dit BussetChristian CotsoglouWilliam P. HarrisNevena DamjanovGianluca MasiLorenza RimassaNicola PersoneniFadi BraitehVittorina ZagonelKyriakos P. PapadopoulosTerence HallYunxia WangBrian SchwartzJulia KazakinSherrie BhooriFilippo de BraudWalid L. Shaib
- [29] Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinomaBRITISH JOURNAL OF CANCER, 2019, 120 (02) : 165 - 171Mazzaferro, VincenzoEl-Rayes, Bassel F.Busset, Michele Droz DitCotsoglou, ChristianHarris, William P.Damjanov, NevenaMasi, GianlucaRimassa, LorenzaPersoneni, NicolaBraiteh, FadiZagonel, VittorinaPapadopoulos, Kyriakos P.Hall, TerenceWang, YunxiaSchwartz, BrianKazakin, JuliaBhoori, Sherriede Braud, FilippoShaib, Walid L.
- [30] The Co-mutational Spectrum Determines the Therapeutic Response in Murine FGFR2 Fusion-Driven CholangiocarcinomaHEPATOLOGY, 2021, 74 (03) : 1357 - 1370Kendre, GajananMarhenke, SilkeLorz, GeorginaBecker, DianaReineke-Plaass, TanjaPoth, TanjaMurugesan, KarthikeyanKuhnel, FlorianWoller, NormanWirtz, Ralph M.Pich, AndreasMarquardt, Jens U.Saborowski, MichaelVogel, ArndtSaborowski, Anna